SCHEMBL1920146

SCHEMBL1920146

CC(C)c1ccc(Nc2c(C(=O)O)n(C)c3ccncc23)c(Cl)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.39
GFER P55789 1/20 0.39
KMT2A Q03164 1/20 0.39
KDM4C Q9H3R0 3/20 0.38
PTGER4 P35408 4/20 0.37
JAK2 O60674 2/20 0.36
FLT1 P17948 1/20 0.35
KDR P35968 1/20 0.35
SRC P12931 1/20 0.35
FTO Q9C0B1 1/20 0.34
PHGDH O43175 2/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
ROCK2 O75116 1/20 0.34
CSNK2A2 P19784 1/20 0.34
CSNK2B P67870 1/20 0.34
CSNK2A1 P68400 1/20 0.34
ALDH1A1 P00352 1/20 0.34
CYP1A2 P05177 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1920341 0.87 SRC (0.41) MEN1KMT2AFLT1KDRSRC
SCHEMBL1920648 0.84 MAP2K1 (0.42) FLT1KDRCSNK2A2CYP2C9
SCHEMBL1920248 0.75 MAP2K1 (0.47) CYP2C9
SCHEMBL1921135 0.74 MAP2K1 (0.47) CYP2C9
SCHEMBL1921132 0.74 MAP2K1 (0.47) CYP2C9
SCHEMBL1922052 0.73 GAA (0.44) MEN1KMT2ASRCSMN1; SMN2CSNK2A2
SCHEMBL1920655 0.72 DHODH (0.38) KDM4C
SCHEMBL12533769 0.72 MAP2K1 (0.57)
SCHEMBL13015240 0.70 MAP2K1 (0.55) MEN1KMT2ACSNK2A2CYP2C9
SCHEMBL12533777 0.70 MAP2K1 (0.53) CSNK2A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2099796-B1 AZA-INDOLYL COMPOUNDS AND METHODS OF USE GENENTECH INC (US) 2011-06-01 EP disclosed
US-7855216-B2 Aza-indolyl compounds and methods of use GENENTECH, INC. (US) 2010-12-21 US disclosed
US-7855216-B2 Aza-indolyl compounds and methods of use GENENTECH, INC. (US) 2010-12-21 US disclosed
US-7855216-B2 Aza-indolyl compounds and methods of use GENENTECH, INC. (US) 2010-12-21 US disclosed
US-20080242655-A1 AZA-INDOLYL COMPOUNDS AND METHODS OF USE GENENTECH, INC. 2008-10-02 US disclosed
US-20080242655-A1 AZA-INDOLYL COMPOUNDS AND METHODS OF USE GENENTECH, INC. 2008-10-02 US disclosed
US-20080242655-A1 AZA-INDOLYL COMPOUNDS AND METHODS OF USE GENENTECH, INC. 2008-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080242655-A1 AZA-INDOLYL COMPOUNDS AND METHODS OF USE CDKN1A, MKI67, CCNI MEN1 1496/4885GFER 4679/4885KMT2A 661/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.